Overview

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological malignancies with extramedullary lesions

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Zhejiang University

Collaborator:

Yake Biotechnology Ltd.